F-box and WD repeat domain-containing 7 (FBW7) is a SCF-type E3 ubiquitin ligase targeting a multitude of oncoproteins for degradation. Acting as one of the most important tumor suppressors, it is frequently inactivated in various tumors. In this study we aimed to evaluate the relationship of FBW7 with glioma pathology and prognosis, and examine its effect in glioma malignancies and temozolomide (TMZ)- --
| INTRODUCTION
Glioma, especially the most common subtype, glioblastoma multiforme (GBM), is among the most malignant human tumors. Currently, despite the standard treatment regimen including the maximum extent of surgical resection plus postoperative chemoradiotherapy, the improvement of the median survival period of GBM is still unsatisfactory, which is largely attributed to the therapeutic resistance to temozolomide (TMZ). 1 Previous research has already implicated a complicated molecular network of signaling pathways in mediating the malignance of glioma. Monotherapy targeting 1 gene or signaling pathway usually leads to other compensative oncogenic activation, thus causing therapeutic resistance. 2 Hence, exploring such therapeutic targets that are capable of regulating multiple molecules or signaling pathways in gliomagenesis and TMZ resistance will be beneficial for improvement of glioma treatment.
Since being identified in 1996, the ubiquitin proteasome system (UPS) has been regarded as an important therapeutic target in tumor therapy for its roles in regulating many aspects of the cancer biology by controlling protein turnover. 3, 4 The function of UPS depends on a cascade activation of ubiquitin-related enzymes, which includes ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, and ubiquitin ligase E3. By direct binding to substrates, E3 enzyme determines the specificity of UPS regulation, which includes 2 main subtypes: the anaphase promoting complex (APC) type and the SKP1-CUL1-F-box complex (SCF) type.
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FBW7 is the substrate binding unit of SCF-type E3 ligase which recognizes substrates with conserved phospho-degron motifs (CPD) through its WD40 repeats domain. 5, 6 It is an important tumor suppressor with dominant-negative mutations in a multitude of tumors, including gastric, colorectal, breast, pancreatic, liver, prostate and endometrial cancers, as well as leukemia and osteosarcoma. 5, 7 To date, multiple substrates of FBW7 have been identified, which include a series of important oncoproteins like Cyclin E, c-Myc, Jun, Mcl1 and Sox9 that are involved in the regulation of cell division, apoptosis, differentiation and some classical oncogenic signaling pathways, such as Notch and mTOR. [8] [9] [10] [11] [12] [13] [14] Among them, the distinct regulation of several substrates needs to be examined in glioma cells. FBW7 gene encodes 3 distinctive protein isoforms (a, b, c) each from its own promoter.
Although it has been shown that FBW7b is mostly suppressed in human glioma cell lines, others have controversially reported that FBW7a and c, instead of isoform b, inhibited growth of glioma cells, 15, 16 which implied that the isoform-specific cellular functions of FBW7 in glioma could be comprehensive. Moreover, the impact of FBW7 expression on gliomagenesis and therapeutic resistance as well as the mechanism by which FBW7 affects the glioma malignancy and related substrates remain far from fully elucidated.
In this study, we examined the expression pattern of FBW7 and its prognostic valve in glioma specimens, tested the inhibitory effect of FBW7 overexpression on cell malignancies of glioblastoma with special regard to TMZ chemoresistance, and, finally, explored the underlying mechanisms of FBW7 regulation in cell cycle, apoptosis and the related substrates. Our research aimed to demonstrate that targeting FBW7 is promising for the treatment of glioma.
| MATERIALS AND METHODS

| Cell culture and cell lines
The U251 and U373 cells used in this study were purchased from Cell
Bank of Chinese Academy of Science (Shanghai, China). All cell lines, including the parental glioblastoma cell line and the modified lines described below, were grown in DMEM (Hyclone, USA) supplemented with 10% FBS (Gibco, USA), 100 U/mL penicillin G, 100 mg/mL streptomycin and 1.5 mmol/L L-glutamine. Cells were maintained in monolayer culture at 37°C, in humidified air with 5% CO 2 .
For resistant cell isolation, parental U251 cells were consecutively re-exposed to an incremental TMZ (Tasly, Tianjin, China) pulse commencing at 1 lg/mL to reach the desired concentration for a period of 6 months. Finally, a variant glioma cell line with a 4-fold 50% inhibitory concentration (IC50) was isolated according to our previous experimental procedures and termed U251/TMZ.
| Analyzation of TCGA data
The expression data of FBW7 expression and the clinical information of patients from the Affymetrix microarray were downloaded from the 17 The score of the staining rate was graded by the percentage of positively stained cells: 0% = 0, 1%-25% = 1, 26%-75% = 2 and 76%-100% = 3. The score of staining intensity was also divided into 4 levels: negative = 0, weak = 1, medium = 2 and strong = 3. The final score was the arithmetic product of percentage score and intensity score, with <1 as low expression, 2-4 as medium expression, 5-7 as high expression, and ≥8 as extremely high expression.
| Constructs and transfection
Human FBW7 complementary DNA reversely-transcribed from the longest transcript NM_013233 containing all 3 isoform-encoding sequences (GAGGATCCCCGGGTACCGGTCGCCACCATGAATC) was tagged with enhanced green fluorescent protein (eGFP) and then cloned into the lentiviral vector GV358 (Genechem, Shanghai, China)
to create the complete functional overexpression plasmid named as Lv-FBW7-OE. An shRNA sequence directed against a shared exon of FBW7 with a loop structure (GATCCGCAACAACGACGCC GAATT ACTTCAAGAGACTTTGCCAAAGGTTCCCTTGCTTTTTTG) was constructed and cloned into GV358 vector, and named as shRNA.
Another control lentiviral vector tagged with eGFP was also con- 
| Western blot assay
The whole cell lysate was extracted in RIPA buffer (Beyotime Biotechnology, China) on ice box and then boiled with 59 loading buffer for 5 minutes. Next, 20 lg of total cell proteins were added into the 12% precast gels and separated by SDS PAGE by 120 V for 75 minutes.
After transferring the proteins to the PVDF member, the band of specific protein was detected by monoclonal or polyclonal antibodies.
All the antibodies were purchased from Abcam as follows: FBW7
(ab109617), Ki-67 (ab15580), Aurora B (ab45145), Mcl-1 (ab32087), Notch-1 (ab52627), Caspase-3 (ab13586) and beta-actin (ab6276).
| Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay
Total RNA was extracted from U251 cells and U251/TMZ cells using an RNeasy Mini Kit (Qiagen, Venlo, the Netherlands). First-strand comple- 
| Temozolomide sensitivity assay
The U251 cells and U251/TMZ cells were trypsinized and diluted to | 1003
working solutions into the cell suspension and cultured for 72 hours continuously. IC50 was calculated according to the OD450 nm by MTT assay as previously described. 18 For in vitro cytoxicity testing, U251 cells were cultured in 6-cm dishes until they had reached nearly half confluence and were then treated with Lv-GFP (control), TMZ (8 lg/mL) + LV-GFP, Lv-FBW7-OE, TMZ (8 lg/mL) + Lv-FBW7-OE, shRNA or shRNA + TMZ (8 lg/mL), respectively. After 36 and 72 hours, all the groups of cells were observed for qualitative analysis under a phase contrast microscope. For each time point, cells were harvested and replated onto 96-well plates for subsequent MTT assay.
The formula of the in vitro cell inhibition rate = (1-OD450 nm of treatment group/OD450 nm of control group) 9 100%. F I G U R E 1 FBW7 subexpression in glioma samples. A, Measures of distribution of FBW7 expression according to data obtained from TCGA. B, Relative expression of FBW7 mRNA in low-grade glioma (LGG) and high-grade glioma (HGG) tissues (***P < .001). C,D, Overall and progress-free survival curve by data of FBW7 expression. Statistical difference existed between the FBW7_high group and the FBW7_low group (*P < .05). E, Representative pictures of FBW7 and Ki-67 immunohistochemical staining in glioma tissues at different histological grades. Scale bars = 100 lm. F, Sample frequency of FBW7 immunoactivity in glioma tissues of different grades. G, Respective data of FBW7 and Ki-67 immunoactivity in both LGG group and HGG groups (***P < .001). H, Relevance of FBW7 and Ki-67 immunoactivity (**P < .01, r = .4677) 3 | RESULTS
| Flow cytometric analysis
| Expression of FBW7 was downregulated in glioma
The distribution analysis of TCGA data revealed that relative FBW7 mRNA expressions of all the samples including high grade glioma (HGG) and LGG were concentrated within the lower region (medium = 0.5993, skewness = 1.057, Kurtosis = 2.155; Figure 1A ).
The relative expression of FBW7 mRNA in low grade glioma (1.494 AE 0.1934) was significantly higher than that in high grade glioma (HGG) according to Student's t test (P-value <.001, Figure 1B) . Study of the TCGA data showed that the lower expression of FBW7 was associated with the shorter overall survival (OS) and progress-free survival (PFS) (P-value <.05, log-rank HR = 1.220 and 1.366, respectively; Figure 1C,D) . In the immunohistochemistry assay, the morphological and statistical results confirmed that the expression level of FBW7 was significantly associated with tumor grade (P-value <.001, Figure 1D ,E). In addition, the FBW7 staining scores of LGG were obviously higher than those of HGG with a statistical difference (P-value <.001), and were negatively correlated with the Ki-67 staining scores (P-value <.01, Figure 1F ,G). Moreover, we observed that the localization of FBW7 is scattered from cytoplasm, nucleus to nucleolus, which was due to the used antibody binding to the conserved FBW7 structure determined by the shared exons. Upregulating the expression level of FBW7 in U251 and U373
significantly reduced the number of cells transferred to the lower side of the chamber (P-value <.001 compared with control).
Although no significant increase of invasion was observed in the FBW7-specific shRNA-transfected U373 line, that of the U251 cell line was considerably increased after FBW7 downexpression (P < .01, Figure 2C,D) . As for the migration assay, the migration distance in U251-Lv-FBW7-OE and U373-Lv-FBW7-OE at both 18 and 36 hours after lentivirus transfection was significantly less than that of the other 2 control cell lines (P-value <.001, Fig- ure 2E,G). As expected, there was a similarly increased number of migrated cells at 36 hours by FBW7 downexpression in these 2 cell lines (P < .05, Figure 2E ,G).
| Overexpression of FBW7 increased the sensitivity of glioma cells to temozolomide
Temozolomide has been the first-line drug for chemotherapy of glioma due to its high penetrability to cross the blood-brain barrier and strong DNA toxicity. The cytotoxic effect of TMZ can be affected by complex molecular pathways. 20 Herein, we observed that the expression of FBW7 was markedly inhibited at both protein and mRNA levels in U251/TMZ, a cell line which was isolated in our previous experiment with 4-fold 50% inhibition rate (IC50; data not shown), compared to the parental U251 cell line (P-value <.01 for quantitative RT-PCR, Figure 3A ,B), suggesting the potential role of FBW7 in mediating TMZ response. Furthermore, this finding was convinced by the results that re-expression of FBW7 in the variant U251/TMZ line partly reversed its resistance to TMZ (P-value <.01, Figure 3C ), while reducing FBW7 expression in U251 cells promoted its resistance to TMZ (P-value <.01, Figure 3D ).
To further evaluate the synergistic effect of TMZ and FBW7
overexpression, we performed a cytotoxicity test in U251 cells to mimic the in vivo experiment. From both the morphological and colorimetric observations, TMZ significantly reduced viable U251 cells at both 36 and 72 hours post-treatment, which was consistent with the theory that TMZ induced cell death usually after 1 cycle of cell division for at least 24 hours. Interestingly, when TMZ was given with FBW7 transfection, cell viability was dramatically inhibited at 36 and 72 hours compared to the control, with a much greater inhibition rate than TMZ alone at 72 hours ( Figure 3D ,E). As expected, specific shRNA-induced FBW7 knockdown attenuated the cytotoxity of TMZ, as shown in Figure 3D ,E, with a reduced inhibition rate in the TMZ + Lv-FBW7-OE-sh group relative to the TMZ alone group at 72 hours.
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| Overexpression of FBW7 increased G2/M arrest and apoptotic death
Previous studies have proved that FBW7 can regulate several cell cycle-associated proteins, such as kinase Aurora B and cyclin E. 8, 21 In light of determining the regulating effect of FBW7 on cell division of glioma, FC analysis was applied. It was shown that U251 cells stably transfected with Lv-FBW7-OE exerted higher proportion of G2/ M phase than Lv-GFP transfected or parental control (P-value <.001). It is commonly accepted that G2/M arrest is critical for TMZ toxicity. 22 Consistent with this, TMZ alone caused a much higher percentage of G2/M phase than other groups, which was further increased when co-treated with Lv-FBW7-OE transfection (Figure 4B) . In contrast, FBW7 downexpression in U251 cells and TMZ Caspase-3 at 24 and 72 hours in a time-dependent manner. These findings were in accordance with the viability-time curve in Figure 2 and may partially explain the proliferation inhibition of glioma cells.
Notably, it was found that Notch1 expression was regulated at an earlier time after FBW7 transfection, suggesting a distinct role of Notch1 in the inhibition of cell migration in less than 24 hours with FBW7 overexpression ( Figure 4G ). Prior research has demonstrated that FBW7 is frequently inactivated for its mutation in a multitude of tumors, including gastric, colorectal, breast, pancreatic, liver cancers and leukemia. With a mutation rate of 6% to 35%, it is considered to be the most common tumor suppressor right behind p53 and PTEN. 7 In addition, many upstream molecules, such as transcriptional factors, kinases and microRNA, can also regulate FBW7 either transcriptionally or posttranslationally. 24 For example, 1 study has reported that a p53- Representative flow cytometry pictures of cell apoptosis in different groups, which are quantitatively presented in histograms. E, Protein changes of Aurora B, cleaved-caspase3, Mcl-1 and Notch1 in U251 cells were detected by western blot at 24 and 72 h, respectively. F, The protein levels of above FBW7 substrates with temozolomide (TMZ) and TMZ plus Lv-FBW7-OE treatment by western blot assay. (*P < .05, **P < .01, ***P < .001 compared to Lv-GFP; ##P < .01 compared to TMZ) FBW7-Aurora B axis, which identified FBW7 as a transcriptional target of p53. 21 Another study found that FBW7 could be phosphorylated and destabilized by ERK kinase. 25 More intriguingly, just before this work was finished, Yang's team discovered a novel circ-FBW7 in glioma cells, which is able to antagonize the inhibitory effect of USP28 on FBW7a so as to degrade c-Myc. 26 In the present study, we found that FBW7 was both downregulated at mRNA level by interrogating the TCGA database and at protein level by immunohistochemistry in glioma tissues. This might be the comprehensive result of mutation and upstream deregulation of FBW7 and requires further investigation. Our data also revealed a diffuse cellular distribution of FBW7 including the cytoplasm, nucleus and nucleolus, which was consistent with the diverse subcellular location of the 3 FBW7 isoforms reported in previous studies. 16 The lethality of glioma is largely attributed to its malignant phenotypes, such as proliferation, migration and invasion, which are controlled by multiple molecules or signaling pathways. Cell proliferation is tightly associated with the cell cycle, which is rigidly regulated by a series of kinases, among which Cyclin E and Aurora B are 2 important FBW7 substrates involved in the promotion of G1/S and G2/M transition, respectively. 5, 8, 21 Previous studies have implicated the role of FBW7 in the regulation of cell proliferation in colon, breast and kidney cancers. 7 In our study, we found that forced FBW7 expression inhibited the proliferation of glioma cells. It increased the ratio of G2/M and led to time-dependent Aurora B downregulation, whereas FBW7 knockdown promoted cell proliferation with significantly reduced G2/M proportion, which suggests that the effect of FBW7 on glioma tumorigenesis could be partially explained by FBW7-mediated Aurora B expression. We also noticed that there were similar changes in G1 proportion with Lv-FBW7-OE or shRNA transfection, suggesting that cyclin E is perhaps involved in FBW7-induced cycle distribution; however, the trend was much less significant than G2/M. Cell migration and invasion are controlled by many biological processes. One of the most common mechanisms is the induction of epithelial-mesenchymal transition (EMT 
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